Hostname: page-component-848d4c4894-p2v8j Total loading time: 0 Render date: 2024-05-01T18:07:25.625Z Has data issue: false hasContentIssue false
  • English
  • Français

The value of serum N-terminal pro-brain natriuretic peptide levels in the differential diagnosis and follow-up of congestive cardiac failure and respiratory distress due to pulmonary aetiologies in infants and children

Published online by Cambridge University Press:  08 June 2010

Melike Sezgin Evim ,
Birsen Ucar ,
Zübeyir Kilic  and
Omer Colak
Melike Sezgin Evim*
Affiliation:
Department of Pediatric Cardiology, Eskisehir Osmangazi University, Faculty of Medicine, 26480, Eskisehir, Turkey
Birsen Ucar
Affiliation:
Department of Pediatric Cardiology, Eskisehir Osmangazi University, Faculty of Medicine, 26480, Eskisehir, Turkey
Zübeyir Kilic
Affiliation:
Department of Pediatric Cardiology, Eskisehir Osmangazi University, Faculty of Medicine, 26480, Eskisehir, Turkey
Omer Colak
Affiliation:
Department of Pediatric Cardiology, Eskisehir Osmangazi University, Faculty of Medicine, 26480, Eskisehir, Turkey
*
Correspondence to: Dr M. S. Evim, Faculty of Medicine, Department of Pediatric Cardiology, Eskisehir Osmangazi University, 26480, Eskisehir, Turkey. Tel: +90 222 2392979/2758; Fax: +90 222 2393772; E-mail: melikevim@yahoo.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

We aimed to determine whether N-terminal pro-brain natriuretic peptide can differentiate between cardiac and pulmonary aetiologies of dyspnoea, if N-terminal pro-brain natriuretic peptide can be used for evaluating the effect of treatment in cardiac failure, and for predicting severe pulmonary diseases that are complicated by cardiac failure.

Methods

In all, 76 children with dyspnoea were enrolled; 41 of them suffered cardiac failure – 25 caused by cardiac disease, 16 caused by pulmonary disease – and 35 had dyspnoea due to pulmonary disease. The control group consisted of 32 children. We calculated Ross scores, analysed N-terminal pro-brain natriuretic peptide levels, and evaluated left ventricular systolic functions by echocardiography.

Results

N-terminal pro-brain natriuretic peptide levels were significantly higher in children with cardiac failure than in those with pulmonary disease and in controls (medians 7321, 241, 87.71 picograms per millilitre, respectively), were higher in children with cardiac failure due to pulmonary disease than in those with only pulmonary disease (medians 2728, 241 picograms per millilitre, respectively), and were higher in children who died from cardiac failure than in survivors (p < 0.05). After treatment of cardiac failure, N-terminal pro-brain natriuretic peptide levels decreased significantly (p < 0.001). The cut-off level of N-terminal pro-brain natriuretic peptide for differentiating cardiacfailure from pulmonary disease was 726.8 picograms per millilitre, sensitivity 100%, specificity 94.3%.

Conclusions

N-terminal pro-brain natriuretic peptide levels can differentiate dyspnoea due to cardiac failure from pulmonary diseases. It can also be used to monitor the effects of treatment of cardiac failure and to estimate the prognosis, as well as to predict pulmonary diseases that are complicated with cardiac failure.

Keywords

N-terminal pro-brain natriuretic peptidedyspnoeachild
Type
Original Articles
Information
Cardiology in the Young , Volume 20 , Issue 5 , October 2010 , pp. 495 - 504
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Francis, GS, Gassler, JP, Sonnenblick, EH. Heart Failure. In Fuster C, Alexander RW, O’Rourke RA (eds). The Heart, 10th edn. International Edition, McGraw-Hill, New York, 2001; 653–685.Google Scholar
2. Jefferies, JL, Chang, AC. The neurohormonal axis and biochemical markers of heart failure. Cardiol Young 2005; 15: 333–344.CrossRefGoogle ScholarPubMed
3. Valderheyden, M, Bartunek, J, Goethals, M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004; 6: 261–268.CrossRefGoogle Scholar
4. Hall, C. Essential biochemistry and physiology of (NT-pro) brain natriuretic peptide. Eur J Heart Fail 2004; 6: 257–260.CrossRefGoogle Scholar
5. Weber, M, Hamm, C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92: 843–849.CrossRefGoogle ScholarPubMed
6. Ambrose, TM. A review of the clinical utility of NT-proBNP in the diagnosis, prognosis and therapy monitoring of patients with congestive heart failure. J Clin Ligand Assay 2003; 25: 160–166.Google Scholar
7. Cowie, MR, Struthers, AD, Wood, DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349–1353.CrossRefGoogle ScholarPubMed
8. Mir, TS, Marohn, S, Laer, S, Eiselt, M, Grollmus, O, Weil, J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and children with congestive heart failure. Pediatrics 2002; 110: 76–81.CrossRefGoogle ScholarPubMed
9. Mueller, T, Gegenhuber, A, Poelz, W, Haltmayer, M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005; 91: 606–612.CrossRefGoogle ScholarPubMed
10. Murray, H, Cload, B, Collier, CP, Sivilotti, ML. Potential impact of N-terminal pro-BNP testing on the emergency department evaluation of acute dyspnea. CJEM 2006; 8: 251–258.CrossRefGoogle ScholarPubMed
11. Moe, GM. B-type natriuretic peptide in heart failure. Curr Opin Cardiol 2006; 21: 208–214.CrossRefGoogle ScholarPubMed
12. Koulouri, S, Acherman, RJ, Wong, PC, Chan, LS, Lewis, AB. Utilty of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric with respiratory distress. Pediatr Cardiol 2004; 25: 341–346.CrossRefGoogle Scholar
13. Cohen, S, Springer, C, Avital, A. Amino-terminal pro-brain natriuretic peptide: Heart or lung disease in pediatric respiratory distress? Pediatrics 2005; 115: 1347–1350.CrossRefGoogle ScholarPubMed
14. Dreyer, WJ, Fisher, DJ. Clinical Recognition and management of chronic congestive heart failure. In Garson A, Bricker JT, Fisher DJ and Neish SR (eds). The science and practice of pediatric cardiology, 2nd edn. Williams and Wilkins, Baltimore, 1998; 1582–1587.Google Scholar
15. James, N, Smith, M. Treatment of heart failure in children. Current Paediatrics 2005; 15: 539–548.CrossRefGoogle Scholar
16. Koch, A, Singer, H. Normal values of B type natriuretic peptide in infants, children and adolescents. Heart 2003; 89: 875–878.CrossRefGoogle ScholarPubMed
17. Mir, TS, Flato, M, Falkenberg, J, et al. Plasma consentrations of N-terminal brain natriuretic peptide in healthy children, adolescents and young adults: effect of age and gender. Pediatr Cardiol 2006; 27: 73–77.CrossRefGoogle Scholar
18. Cowley, CG, Bradley, JD, Shaddy, RE. B-type natriuretic peptide levels in congenital heart disease. Pediatr Cardiol 2004; 25: 336–340.CrossRefGoogle ScholarPubMed
19. Koch, A, Zink, S, Singer, H. B-type natriuretic peptide in paediatric patents with congenital heart disease. Eur Heart J 2006; 27: 861–866.CrossRefGoogle Scholar
20. Shann, F, MacGregor, D, Richens, J, Coakley, J. Cardiac failure in children with pneumonia in Papua New Guinea. Pediatr İnfect Dis J 1998; 17: 1141–1443.CrossRefGoogle ScholarPubMed
21. İlten, F, Şenocak, F, Zorlu, P, Teziç, T. Cardiovascular changes in children with pneumonia. Turk J Pediatr 2003; 45: 306–310.Google ScholarPubMed
22. Wang, YL, Liu, W, Jiang, P. Myokardial protective effect of puerarin injection in children with severe pneumonia. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005; 25: 502–504.Google Scholar
23. Ross, RD, Bollinger, RO, Pinsky, WW. Grading the severity of congestive heart failure in infants. Pediatr Cardiol 1992; 13: 72–75.CrossRefGoogle ScholarPubMed
24. Laer, S, Mir, TS, Behn, F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 2002; 143: 916–922.CrossRefGoogle ScholarPubMed
25. An, JD, Zhang, YP, Zhou, JH. Levels of serum brain natriuretic peptide in children with congestive heart failure or with severe pneumonia. Zhongguo Dang Dai Er Ke Za Zhi 2006; 8: 201–204.Google ScholarPubMed
26. Meliones, JN, Cheifetz, IM. Pulmonary physiology and heart-lung interactions. In Garson A, Bricker JT, Fisher DJ and Neish SR (eds). The Science and Practice of Pediatric Cardiology, 2nd edn. Williams and Wilkins, Baltimore, 1998; 279–312.Google Scholar
27. Seedat, MA, Feldman, C, Skoularigis, J, Prommnitz, DA, Smith, C, Zwi, S. A study of acute community-acquired pneumonia, including details of cardiac changes. Q J Med 1993; 86: 669–675.CrossRefGoogle ScholarPubMed
28. Bayes-Genis, A, Santalo-Bel, M, Zapico-Muniz, E, et al. N-terminal probrain natriuretic peptide in the emergency diagnosis and in-hospital monitoring of patients with dysnoea and ventricular dysfunction. Eur J Heart Fail 2004; 6: 301–308.CrossRefGoogle Scholar
29. Bettencourt, P. NT pro-BNP and BNP: biomakers for heart failure management. Eur J Heart Fail 2004; 6: 359–363.CrossRefGoogle Scholar
30. Suda, K, Matsumura, M, Matsumoto, M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003; 45: 249–254.CrossRefGoogle ScholarPubMed
31. Maeda, K, Tsutamoto, T, Wada, A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587–1593.CrossRefGoogle ScholarPubMed
32. Pfister, R, Scholz, M, Wielckens, K, Erdmann, E, Schneider, CA. Use of NT pro-BNP in routine testing and comparison to BNP. Eur J Heart Fail 2004; 6: 289–293.CrossRefGoogle ScholarPubMed
33. Seino, Y, Ogawa, A, Yamashita, T, et al. Application of NT pro-BNP and BNP measurements in cardiac care: a more discerning marker of the detection and evaluation of heart failure. Eur J Heart Fail 2004; 6: 295–300.CrossRefGoogle Scholar
34. Wu, YR, Chen, SB, Huang, MR, Zhang, YQ, Sun, K, Chen, S. Diagnostic value of plasma concentration of pro-brain natriuretic peptide in congestive heart failure in pediatric patients with ventricular septal defects. Zhonghua Er Ke Za Zhi 2005; 43: 161–164.Google ScholarPubMed
35. Maisel, A. B-type natriuretic peptide levels: a potential novel “white count” for congestive heart failure. J Card Fail 2001; 7: 183–193.CrossRefGoogle Scholar
36. Mir, TS, Falkenberg, J, Friedrich, B, et al. Levels of brain natriuretic peptide in children with right ventricular overload due to congenital cardiac disease. Cardiol Young 2005; 15: 396–401.CrossRefGoogle ScholarPubMed